Shotaro Kamata

Assistant professor

Showa Pharmaceutical University

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Shotaro Kamata is an Assistant Professor at Showa Pharmaceutical University in Japan. His research focuses on PPAR (Peroxisome Proliferator-Activated Receptor) targeting, particularly in the context of nonalcoholic fatty liver disease and related metabolic disorders. His recent publications explore the recruitment of coactivators to PPAR ligand-binding domains and the structural insights into various investigational drugs. Dr. Kamata employs techniques such as dual-emission FRET and X-ray crystallography in his studies.

Articles (12)

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (3)

Yasuo Watanabe

Professor

Showa Pharmaceutical University

JAPAN

View details

Takuji Oyama

Professor

University of Yamanashi

JAPAN

View details

Isao Ishii

Professor

Showa Pharmaceutical University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Shotaro Kamata

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Competitive Ligand-Induced Recruitment of Coactivators to Specific PPARα/δ/γ Ligand-Binding Domains Revealed by Dual-Emission FRET and X-Ray Diffraction of Cocrystals

Different Coactivator Recruitment to Human PPARα/δ/γ Ligand-Binding Domains by Eight PPAR Agonists to Treat Nonalcoholic Fatty Liver Disease

Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease

Functional and Structural Insights into the Human PPARα/δ/γ Targeting Preferences of Anti-NASH Investigational Drugs, Lanifibranor, Seladelpar, and Elafibranor

Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate

A High-Methionine Diet for One-Week Induces a High Accumulation of Methionine in the Cerebrospinal Fluid and Confers Bipolar Disorder-like Behavior in Mice.

Preparation of co-crystals of human PPAR<b>α</b>-LBD and ligand for high-resolution X-ray crystallography.

Crystal Structures of the Human Peroxisome Proliferator-Activated Receptor (PPAR)α Ligand-Binding Domain in Complexes with a Series of Phenylpropanoic Acid Derivatives Generated by a Ligand-Exchange Soaking Method.

Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.

[PPARα-Ligand Binding Modes Revealed by X-ray Crystallography].

PPARα Ligand-Binding Domain Structures with Endogenous Fatty Acids and Fibrates

Cytotoxicity comparison of 35 developmental neurotoxicants in human induced pluripotent stem cells (iPSC), iPSC-derived neural progenitor cells, and transformed cell lines.

Collaborators (3)

Yasuo Watanabe

Takuji Oyama

Isao Ishii

Make your next move.